RSPH9

Across TCGA pan-cancer cohorts, RSPH9 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RSPH9 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RSPH9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RSPH9 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM and LSCC are the cancer types where RSPH9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.902	0.294	.036	6	view →
LSCC	DFS	Quartile	II,III,IV	0.845	1.000	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RSPH9–GBM (OS)

Open the GBM breakdown →